V
VIRIDIAN THERAPEUTICS INC
NASDAQ: VRDN (Viridian Therapeutics, Inc.)
最近更新时间: 7小时之前13.57
-0.10 (-0.73%)
| 前收盘价格 | 13.67 |
| 收盘价格 | 13.39 |
| 成交量 | 645,426 |
| 平均成交量 (3个月) | 902,747 |
| 市值 | 1,107,203,456 |
| 价格/销量 (P/S) | 3.25 |
| 股市价格/股市净资产 (P/B) | 2.44 |
| 52周波幅 | |
| 利润日期 | 6 Aug 2025 - 11 Aug 2025 |
| 营业利益率 (TTM) | -121,488.89% |
| 稀释每股收益 (EPS TTM) | -3.07 |
| 总债务/股东权益 (D/E MRQ) | 3.44% |
| 流动比率 (MRQ) | 15.43 |
| 营业现金流 (OCF TTM) | -232.32 M |
| 杠杆自由现金流 (LFCF TTM) | -136.82 M |
| 资产报酬率 (ROA TTM) | -30.32% |
| 股东权益报酬率 (ROE TTM) | -48.48% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Viridian Therapeutics, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
2.4
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 2.38 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.12% |
| 机构持股比例 | 114.06% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 45.00 (RBC Capital, 231.61%) | 购买 |
| 中 | 36.00 (165.29%) | |
| 低 | 27.00 (Goldman Sachs, 98.97%) | 购买 |
| 平均值 | 36.00 (165.29%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 12.84 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 20 May 2025 | 36.00 (165.29%) | 购买 | 13.82 |
| 07 May 2025 | 36.00 (165.29%) | 购买 | 12.29 | |
| Goldman Sachs | 07 May 2025 | 27.00 (98.97%) | 购买 | 12.29 |
| JMP Securities | 07 May 2025 | 38.00 (180.03%) | 购买 | 12.29 |
| RBC Capital | 07 May 2025 | 45.00 (231.61%) | 购买 | 12.29 |
| HC Wainwright & Co. | 23 Apr 2025 | 34.00 (150.55%) | 购买 | 13.51 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合